Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
NCT07415525Phase 2Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of arcotatug tavatecan in pancreatic cancer (PC), sponsored by Zhejiang University. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
arcotatug tavatecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07415525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07415525.